• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by abrdn Life Sciences Investors Shares of Beneficial Interest

    5/24/24 9:13:37 AM ET
    $HQL
    Investment Managers
    Finance
    Get the next $HQL alert in real time by email
    DEFA14A 1 tm2415427d1_defa14a.htm DEFA14A

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.         )

     

    Filed by the Registrant     [X]

     

    Filed by a Party other than the Registrant     [   ]

     

    Check the appropriate box:

     

    [   ]Preliminary Proxy Statement
    [   ]Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    [   ]Definitive Proxy Statement
    [X]Definitive Additional Materials
    [   ]Soliciting Material under §240.14a-12

     

    abrdn Life Sciences Investors

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    [X]No fee required.
    [   ]Fee paid previously with preliminary materials.
    [   ]Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11.

     

     

     

     

    abrdn Life Sciences Investors (NYSE: HQL)
    (formerly Tekla Life Sciences Investors)

     

     

    Shareholder Services

     

     

     

    Text Box: IMPORTANT NOTICE

     

    Re: abrdn Life Sciences Investors (NYSE: HQL) formerly Tekla Life Sciences Investors

     

    Dear Shareholder:

     

    We have tried unsuccessfully to contact you, whether by mail or by phone, regarding a very important matter concerning your investment with abrdn Life Sciences Investors (formerly Tekla Life Sciences Investors). This matter pertains to important operating initiatives for the Fund for which we need your consideration and response.

     

    It is very important that we speak to you regarding this matter. Please call toll-free at 1-800-967-7574 between 9:00 a.m. and 10:00 p.m. Eastern Time, Monday through Friday. At the time of the call, please reference the Investor ID listed below.

     

    INVESTOR PROFILE:

     

    Investor ID:  XXXXXXXX  Security ID:  XXXXXXXX
    Shares owned:  XXXXXXXXX  Household ID:  XXXXXXXX 

     

    There is no confidential information required and the call will only take a few moments of your time. Please contact us as soon as possible. Thank you for your time and consideration.

     

    Sincerely,

     

    Megan Kennedy

    Vice President and Secretary

     

     

     OFFICIAL BUSINESS  This document relates to your investment in abrdn Life Sciences Investors (formerly Tekla Life Sciences Investors).

     

     

    Get the next $HQL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HQL

    DatePrice TargetRatingAnalyst
    More analyst ratings